Regulation, anti-doping, and trials
The science is exciting, but the regulatory facts are blunt: MOTS-c is not an FDA-approved drug, it was on the FDA…
Not approved, on the WADA list, and without a completed efficacy trial
The science is exciting, but the regulatory facts are blunt: MOTS-c is not an FDA-approved drug, it was on the FDA compounding Category 2 list of substances flagged for significant safety risk until it left Category 2 with the FDA’s 22 April 2026 page update, after the nominators withdrew the nomination and the FDA moved it to a separate "nominated but withdrawn" list (withdrawal is not approval, and it is still not authorized for compounding), and it is explicitly on the 2026 WADA Prohibited List as a metabolic modulator (AMPK activator). Athletes and clinicians both need these facts before any conversation about use.
This unit lays out the regulatory landscape plainly, walks through what it means for an athlete versus a researcher, and looks honestly at the clinical-trial picture: mostly biomarker observation, plus a first phase 2 efficacy trial that started recruiting in 2026 and has reported nothing yet. Separating investigational science from market and clinical reality is a core part of being literate about this peptide.